Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07209202

Fructose Intestinal Gluconeogenesis

Fructose Metabolism Effects on the Liver: Unraveling the Role of Defective Intestinal GNG in Individuals With Obesity

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Touro University, California · Academic / Other
Sex
All
Age
20 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.

Detailed description

Qualified participants will undergo a sugar tolerance test at baseline and then randomized to undergo four separate outpatient tracer/feeding studies in a crossover fashion. After an overnight fast, a six-hour fed tracer study will be initiated, during which participants will consume liquid meals containing stable isotopes at regular intervals and receive other isotopes intravenously. Meal composition will differ only by fructose content (High vs. Low) and tracer (oral vs. intravenous 13C-labeled fructose). Blood and urine samples will be collected frequently throughout the study. Each visit will be performed approximately three weeks apart. Vital signs and anthropometrics will be measured at each clinic visit.

Conditions

Interventions

TypeNameDescription
OTHERHigh fructose mealLiquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein.
OTHERLow fructose meal55% total carbohydrate (6% fructose), 30% fat, 15% protein.
OTHER13C labeled fructose, oralTracer amount of 13C labeled fructose administered orally in the meals.
OTHER13C labeled fructose, intravenousTracer amount of 13C fructose administered intravenously

Timeline

Start date
2026-03-02
Primary completion
2030-06-01
Completion
2030-06-01
First posted
2025-10-06
Last updated
2026-03-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07209202. Inclusion in this directory is not an endorsement.